CustomerValidation
- •AmJCancerRes.2017Apr1;7(4):903-912.
- •UniversidadedoPorto.2015-11-16.
- •UniversidadedoPorto.Setembro/2015.
- •HarvardMedicalSchoolLINCSLIBRARY
Description | Paclitaxelisapotentanticanceragentknowntopromotemicrotubule(MT) assembly,inhibitMTdepolymerization,andchangeMTdynamicsrequiredformitosisandcellproliferation. |
---|---|
IC50&Target | IC50:4nM(MT) |
InVitro | Paclitaxelat0.1,0.5,and1μMreducestheproliferationandsurvivalofCCRF-HSB-2cellsinadose-dependentfashionandthattheIC50valueoftaxolisabout0.25μM[1].Paclitaxeldirectlyassociateswiththeendoplasmicreticulumtostimulatethereleaseofcalciumintothecytosol,contributingtotheinductionofapoptosis[2]. |
InVivo | InaSCIDmousexenograftmodel,lowdosemetronomicPaclitaxeltreatmentdecreaseslungdisseminationofEGI-1cellswithoutsignificantlyaffectingtheirlocaltumorgrowth[3].Lowdosesofpaclitaxelpromotlivermetastasisinmousexenografts,whichcorrelatswithchangesinestrogenmetabolisminthehostliver[4].Paclitaxel(2mg/kgpertreatment,blackcircles)inducesmechanicalhypersensitivityintheglabrousskinofthehindpaw[5]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KinaseAssay [1] | Todeterminewhichcaspasesareinvolvedinapoptosisinducedbytaxol,caspase-3inhibitor(DEVD-CHO),caspase-6inhibitor(Z-VEID-FMK),caspase-8inhibitor(Z-IETD-FMKorIETD-CHO),caspase-9inhibitors(Z-LEHD-FMKorLEHD-CHO),andcaspase-10inhibitor(Z-AEVD-FMK)areused.Thesecaspaseinhibitorsaredissolvedindimethylsulfoxide(Me2SO);thefinalconcentrationofMe2SOis0.1%.Cells(5×105)arepreincubatedinthepresenceorabsenceof100μM eachoftheseinhibitorsfor3hat37°Cthentreatedwithorwithout0.1,0.5,and1μM Paclitaxelfor48handprocessedforannexinVbindingassay.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||||||||||||||||
CellAssay [1] | 1×104cellsareplatedin100μLofthegrowthmediuminthepresenceorabsenceofincreasingconcentrations(0.1-1μM)oftaxolin96-wellplatesandculturedat37°Cin5%CO2for12-48h.Thecellsarethenincubatedwith25μLofMTT(5mg/mL)at37°Cfor4h.Afterdissolvingthecrystalswith0.04 N HClinisopropanol,theplatesarereadinamicroplatereaderat570nm.Theconcentrationofdrugthatinhibitscellsurvivalby50%(IC50)isdeterminedfromcellsurvivalplots.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. AnimalAdmiNISTration | [5] Paclitaxelisdissolvedat25mg/mLin1:1CremophorEL:ethanolandfreshlydiluted1:12.5in0.9%sterilesalinepriortoinjections. Adult(250-320g)maleSprague-Dawleyratsareusedforallexperiments.Ratsarehousedtwopercageinatemperatureandhumiditycontrolled,ona12h:12hlight:darkschedulewithfoodandwateravailableadlibitum.OneweekfollowingtheDiIinjection,ratsareanesthetizedwithisofluoraneandinjectedintothetailveinwith2mg/kgpaclitaxeloritsvehicle(1:1:23,cremophorEL:ethanol:0.9%saline).Thetailveininjectionisrepeatedthreemoretimeseveryotherdayforatotaloffourinjections.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. References |
Purity:99.60% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|